|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RCOR3 |
Gene summary for RCOR3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RCOR3 | Gene ID | 55758 |
| Gene name | REST corepressor 3 | |
| Gene Alias | RCOR3 | |
| Cytomap | 1q32.2-q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9P2K3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55758 | RCOR3 | LZE2T | Human | Esophagus | ESCC | 8.19e-10 | 6.55e-01 | 0.082 |
| 55758 | RCOR3 | LZE4T | Human | Esophagus | ESCC | 3.76e-17 | 5.70e-01 | 0.0811 |
| 55758 | RCOR3 | LZE7T | Human | Esophagus | ESCC | 1.99e-14 | 6.43e-01 | 0.0667 |
| 55758 | RCOR3 | LZE8T | Human | Esophagus | ESCC | 1.61e-04 | 8.54e-02 | 0.067 |
| 55758 | RCOR3 | LZE24T | Human | Esophagus | ESCC | 1.94e-12 | 2.97e-01 | 0.0596 |
| 55758 | RCOR3 | P1T-E | Human | Esophagus | ESCC | 4.75e-15 | 5.46e-01 | 0.0875 |
| 55758 | RCOR3 | P2T-E | Human | Esophagus | ESCC | 2.36e-32 | 4.62e-01 | 0.1177 |
| 55758 | RCOR3 | P4T-E | Human | Esophagus | ESCC | 6.37e-38 | 7.97e-01 | 0.1323 |
| 55758 | RCOR3 | P5T-E | Human | Esophagus | ESCC | 7.08e-28 | 4.95e-01 | 0.1327 |
| 55758 | RCOR3 | P8T-E | Human | Esophagus | ESCC | 8.05e-21 | 2.63e-01 | 0.0889 |
| 55758 | RCOR3 | P9T-E | Human | Esophagus | ESCC | 7.78e-13 | 2.27e-01 | 0.1131 |
| 55758 | RCOR3 | P10T-E | Human | Esophagus | ESCC | 1.86e-28 | 4.08e-01 | 0.116 |
| 55758 | RCOR3 | P11T-E | Human | Esophagus | ESCC | 1.83e-10 | 3.96e-01 | 0.1426 |
| 55758 | RCOR3 | P12T-E | Human | Esophagus | ESCC | 1.37e-22 | 2.59e-01 | 0.1122 |
| 55758 | RCOR3 | P15T-E | Human | Esophagus | ESCC | 6.41e-29 | 5.52e-01 | 0.1149 |
| 55758 | RCOR3 | P16T-E | Human | Esophagus | ESCC | 3.66e-24 | 4.37e-01 | 0.1153 |
| 55758 | RCOR3 | P17T-E | Human | Esophagus | ESCC | 4.01e-08 | 2.18e-01 | 0.1278 |
| 55758 | RCOR3 | P19T-E | Human | Esophagus | ESCC | 9.26e-03 | 3.24e-01 | 0.1662 |
| 55758 | RCOR3 | P20T-E | Human | Esophagus | ESCC | 2.71e-18 | 4.31e-01 | 0.1124 |
| 55758 | RCOR3 | P21T-E | Human | Esophagus | ESCC | 5.90e-11 | 2.61e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00987321 | Lung | AIS | macromolecule deacylation | 23/1849 | 116/18723 | 8.77e-04 | 1.19e-02 | 23 |
| GO:00165706 | Prostate | BPH | histone modification | 120/3107 | 463/18723 | 1.73e-07 | 3.89e-06 | 120 |
| GO:00356013 | Prostate | BPH | protein deacylation | 32/3107 | 112/18723 | 1.03e-03 | 6.46e-03 | 32 |
| GO:00064763 | Prostate | BPH | protein deacetylation | 29/3107 | 101/18723 | 1.59e-03 | 9.28e-03 | 29 |
| GO:00987323 | Prostate | BPH | macromolecule deacylation | 32/3107 | 116/18723 | 1.94e-03 | 1.10e-02 | 32 |
| GO:001657013 | Prostate | Tumor | histone modification | 126/3246 | 463/18723 | 5.51e-08 | 1.65e-06 | 126 |
| GO:003560112 | Prostate | Tumor | protein deacylation | 33/3246 | 112/18723 | 1.05e-03 | 6.77e-03 | 33 |
| GO:000647612 | Prostate | Tumor | protein deacetylation | 30/3246 | 101/18723 | 1.50e-03 | 9.27e-03 | 30 |
| GO:009873211 | Prostate | Tumor | macromolecule deacylation | 33/3246 | 116/18723 | 2.00e-03 | 1.16e-02 | 33 |
| GO:00165752 | Prostate | Tumor | histone deacetylation | 23/3246 | 82/18723 | 1.07e-02 | 4.42e-02 | 23 |
| GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
| GO:00356017 | Thyroid | PTC | protein deacylation | 58/5968 | 112/18723 | 9.29e-06 | 1.05e-04 | 58 |
| GO:00165756 | Thyroid | PTC | histone deacetylation | 45/5968 | 82/18723 | 1.34e-05 | 1.45e-04 | 45 |
| GO:00064767 | Thyroid | PTC | protein deacetylation | 53/5968 | 101/18723 | 1.36e-05 | 1.47e-04 | 53 |
| GO:00987327 | Thyroid | PTC | macromolecule deacylation | 58/5968 | 116/18723 | 3.59e-05 | 3.36e-04 | 58 |
| GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
| GO:003560114 | Thyroid | ATC | protein deacylation | 61/6293 | 112/18723 | 4.37e-06 | 4.79e-05 | 61 |
| GO:000647614 | Thyroid | ATC | protein deacetylation | 56/6293 | 101/18723 | 5.15e-06 | 5.57e-05 | 56 |
| GO:001657512 | Thyroid | ATC | histone deacetylation | 47/6293 | 82/18723 | 8.75e-06 | 8.81e-05 | 47 |
| GO:009873213 | Thyroid | ATC | macromolecule deacylation | 61/6293 | 116/18723 | 1.89e-05 | 1.72e-04 | 61 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RCOR3 | SNV | Missense_Mutation | novel | c.1139G>T | p.Gly380Val | p.G380V | Q9P2K3 | protein_coding | tolerated(0.63) | possibly_damaging(0.881) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| RCOR3 | SNV | Missense_Mutation | rs773567709 | c.1340N>A | p.Arg447Gln | p.R447Q | Q9P2K3 | protein_coding | tolerated(0.6) | benign(0) | TCGA-B6-A0RM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RCOR3 | SNV | Missense_Mutation | c.1466N>T | p.Gln489Leu | p.Q489L | Q9P2K3 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RCOR3 | SNV | Missense_Mutation | c.1263N>C | p.Glu421Asp | p.E421D | Q9P2K3 | protein_coding | tolerated(0.39) | benign(0) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| RCOR3 | SNV | Missense_Mutation | rs763801630 | c.1409N>C | p.Asn470Thr | p.N470T | Q9P2K3 | protein_coding | tolerated(0.38) | benign(0.402) | TCGA-E9-A227-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| RCOR3 | SNV | Missense_Mutation | novel | c.173N>T | p.Gly58Val | p.G58V | Q9P2K3 | protein_coding | tolerated(0.15) | probably_damaging(0.999) | TCGA-EA-A556-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RCOR3 | SNV | Missense_Mutation | novel | c.1312N>C | p.Glu438Gln | p.E438Q | Q9P2K3 | protein_coding | tolerated(0.16) | benign(0.192) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RCOR3 | SNV | Missense_Mutation | rs768561869 | c.1451C>T | p.Pro484Leu | p.P484L | Q9P2K3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RCOR3 | SNV | Missense_Mutation | c.1273G>A | p.Ala425Thr | p.A425T | Q9P2K3 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RCOR3 | SNV | Missense_Mutation | rs773567709 | c.1340N>A | p.Arg447Gln | p.R447Q | Q9P2K3 | protein_coding | tolerated(0.6) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |